Two weeks back, we reported that PASO was trading at its 52-week low, and we felt that the bottom was being solidified in place. Trading on Thursday pushed the price of PASO stock to .0009, which incidentally, could have made savvy traders 50-80% in gains.
As if the increased activity wasn’t enough to be satisfied, the company came with some post-market blockbuster news that could help fuel the continuation of momentum to close out the week strong.
PASO is a perfect example of why patience is key, even with some of our shorter-term plays, just a few weeks time can make a big difference.
HAUPPAUGE, N.Y., Sep 08, 2011 (BUSINESS WIRE) — Patient Access Solutions, Inc. (Pink Sheets: PASO), a leading provider of information technology solutions for the healthcare industry is pleased to announce its EMR management & support solution has been engaged and is being deployed with a Florida based hospital group.
The client is the largest faith based, non profit health care organization in Florida to participate in the EHR (Electronic Health Record) program and has a long standing pedigree as a national leader in the adoption of healthcare IT across its network of 6 hospitals comprising of more than 1,500 beds. This engagement serves as part of its continuing commitment to enable excellent quality care and services, will assist its more than 2,000 physicians in the adoption of Electronic Health Records in their private practices through an EHR Donation Program. The initial implementation expects to generate approximately $3 million in gross revenue over the next year for Patient Access Solutions.
Star Scientific, Inc. CIGX
On Thursday, CIGX cracked into the top -gainers list for NASDAQ stocks. It is always impressive when a NASDAQ stock can increase in value 7% in a single day.
Autumn was a huge season for this stock last year, when the PPS doubled in just a few short months. We are anxious to see what activity this fall season will bring to CIGX.
BioCurex, Inc BOCX
When momentum stocks like this hit our radar screen, we like to keep them high on our watchlist as heavy movers with a high bounce probability.
This morning, we foresee a possible gap up followed by a pullback, which we see as a good opportunity to get in for a quick flip on the bounce. Ultimately we will be watching BOCX closely for the dust to settle after yesterday’s excitement.
Here is the huge news that caused all this commotion:
In a study to be presented at the ISOBM (International Society of Oncology and Biomarkers) annual meeting in October, BioCurex compared the performance of RECAF and free-PSA to discriminate prostate cancer from benign prostate hyperplasia (BPH), a common benign condition that requires no surgical treatment. The RECAF test outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.